J&J’s Spravato Gets EU Okay For Drug-Resistant Depression
Nasal Spray Completes Approval Process Unscathed
Concerns that written interventions might delay the expected EU approval of the novel ketamine-based antidepressant have come to naught.
You may also be interested in...
The EMA has received written interventions from third parties relating to its CHMP opinion that the controversial antidepressant should receive EU approval.
Just over a year ago, AstraZeneca at last returned to growth and set about a reorganization that placed oncology at the heart of its plans for continued success. In Vivo talked to the executive vice-president of its Oncology Business Unit David Fredrickson about how the company hopes to become a major cancer player.
The leading PARP inhibitor gets a new tumor type added to its label after a narrow ODAC vote in favor less than a fortnight ago.